LOS ANGELES, May 6, 2013 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BioSig), a medical device company developing unique clinical solutions for the electrophysiology market, announced that Seth H. Z. Fischer has joined the Company's Board of Directors.
Seth H. Z. Fischer served as Johnson & Johnson's Company Group Chairman and Worldwide Franchise Chairman of the Cardiovascular Care Franchise until his retirement in 2012. He was responsible for Johnson & Johnson's global cardiovascular device business which included Cordis Cardiology/Endovascular and Biosense Webster, a leader in the electrophysiology device market.
Kenneth L. Londoner, BioSig Technologies' Chairman and CEO stated, "It is a great privilege to welcome Seth to our Board of Directors. His leadership experience, industry knowledge and unique perspective will be invaluable to BioSig in our effort to commercialize our PURE EP™ System."
Seth Fischer commented, "BioSig Technologies has a unique proprietary platform which can make an important impact to the electrophysiology field. I look forward to providing guidance to the executive team as the Company advances through clinical trials on the way to commercialization."
About BioSig Technologies, Inc.
BioSig Technologies, Inc. is a medical device company developing unique clinical solutions for the diagnosis and treatment of arrhythmias. BioSig's PURE EP™ System is designed to assist electrophysiologists during the termination of arrhythmias by catheter ablation. The PURE EP System empowers EP physicians to make crucial clinical decisions in real-time by providing clinical information unobtainable with any other equipment presently in the electrophysiology lab.
CONTACT: Lora Mikolaitis, Director of Operations
BioSig Technologies, Inc.
12424 Wilshire Blvd, Suite 745
Los Angeles, CA 90025